Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (Q22242745)

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Molecular genetics of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The use of tricyclic antidepressants in children and adolescents

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Attention-deficit/hyperactivity disorder and comorbidity

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Driving impairments in teens and adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Can inattention/overactivity be an institutional deprivation syndrome?

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Teachers' screening for attention deficit/hyperactivity disorder: comparing multinational samples on teacher ratings of ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Enhancements to the behavioral parent training paradigm for families of children with ADHD: review and future directions.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Sudden death from cardiac causes in children and young adults

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

ADHD drugs and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A chart review of cyproheptadine for stimulant-induced weight loss

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Lead neurotoxicity in children: basic mechanisms and clinical correlates

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Psychometric Properties of the Vanderbilt ADHD Diagnostic Parent Rating Scale in a Referred Population

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Another sudden death in a child treated with desipramine

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Male testosterone linked to high social dominance but low physical aggression in early adolescence

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

ADHD is associated with early initiation of cigarette smoking in children and adolescents

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Randomized trial of a home-based family intervention for children who have deliberately poisoned themselves.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Attention-deficit hyperactivity symptomatology after traumatic brain injury: a prospective study.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Resolved: mania is mistaken for ADHD in prepubertal children

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Combining methylphenidate and clonidine: a clinically sound medication option

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Does maternal ADHD reduce the effectiveness of parent training for preschool children's ADHD?

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A Pharmacokinetic/Pharmacodynamic Study Comparing a Single Morning Dose of Adderall to Twice-Daily Dosing in Children With ADHD

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Magnetic Resonance Imaging of Boys With Attention-Deficit/Hyperactivity Disorder and Their Unaffected Siblings

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Stimulant treatment over five years: adherence, effectiveness, and adverse effects

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Impact of low birth weight on attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Attention Deficit Hyperactivity Disorder (ADHD) is Associated with Early Onset Substance Use Disorders

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Young adult outcome of hyperactive children: adaptive functioning in major life activities

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Stimulant treatment over 5 years: effects on growth.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Treatment of ADHD With Stimulant Medications: Response to Nissen Perspective in The New England Journal of Medicine

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS).

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Safety and tolerability of methylphenidate in preschool children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Pharmacogenetics of methylphenidate response in preschoolers with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Internalizing disorders in childhood

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Young adult follow-up of hyperactive children: antisocial activities and drug use

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Growth on stimulant medication; clarifying the confusion: a review

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Attention deficit hyperactivity disorder in elementary school children in Rhode Island: associated psychosocial factors and medications used

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Clinical implications of a link between fetal alcohol spectrum disorder and attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Methyiphenidate vs. amphetamine: Comparative review

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

What is the prevalence of adult ADHD? Results of a population screen of 966 adults

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Empirically supported psychosocial treatments for attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Social skills training in children with attention deficit hyperactivity disorder: a randomized-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Treatment of ADHD in children with tics: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Shifts in percentiles of growth during early childhood: analysis of longitudinal data from the California Child Health and Development Study

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021

Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina.

1 reference

https://api.crossref.org/works/10.1097%2FCHI.0B013E318054E724

7 January 2021